Related Experiment Videos
Thalidomide: a re-look
J K Grover1, V Vats, R Gopalakrishna
1Department of Pharmacology, All India Institute of Medical Sciences, Ansari Nagar, New Delhi 110029, India.
The National Medical Journal of India
|September 18, 2001
Summary
Thalidomide, initially a sedative, is now a preferred treatment for erythema nodosum leprosum (ENL). Its anti-inflammatory properties also benefit other conditions like lupus and graft-versus-host disease.
Area of Science:
- Immunology
- Pharmacology
- Dermatology
Background:
- Thalidomide was initially marketed as a sedative but was withdrawn due to severe teratogenic effects.
- A serendipitous discovery highlighted its potential in treating erythema nodosum leprosum (ENL).
Purpose of the Study:
- To review established studies on thalidomide's efficacy in various medical conditions.
- To evaluate thalidomide's therapeutic role beyond ENL, considering its anti-inflammatory and immunomodulatory properties.
Main Methods:
- Inclusion of only well-defined studies substantiating thalidomide's efficacy.
- Review of clinical trials and observational data on thalidomide's use.
Main Results:
- Thalidomide is the drug of choice for ENL, recommended by the WHO and approved by the FDA.
- Demonstrated efficacy in dermatological conditions such as systemic lupus erythematosus, discoid lupus erythematosus, actinic prurigo, and prurigo nodularis.
- Therapeutic applications identified in graft-versus-host disease, AIDS-related wasting, aphthous ulcers, and Kaposi's sarcoma.
Conclusions:
- Thalidomide is a safe and effective treatment for ENL and several other conditions when used correctly.
- Its use is recommended for other conditions primarily when standard therapies fail.
- Thalidomide is not indicated as an immunosuppressant in solid organ transplantation but has a role in graft-versus-host disease.